e-CBTi vs Trazodone for Insomnia
Trial Summary
What is the purpose of this trial?
Insomnia is defined as the inability to fall asleep or stay asleep at night and it is one of the most prevalent sleep disorders that can have deleterious impacts on health and this population's quality of life. Currently, both pharmaceutical interventions (trazodone) and cognitive behavioral therapy (CBTi) are widely used to treat patients with insomnia. Although CBTi has been efficacious in many patients, multitude of barriers for receiving treatment such as its limited availability of therapists, high costs and long wait times challenge its ability in sufficiently meeting the population's health needs and demands. To improve the delivery of CBT, electronically delivered CBTi (e-CBTi) has been developed as an accessible and effective alternative intervention for improving sleep outcomes in patients with insomnia. While evidence suggest that e-CBTi is effective when compared to placebos/waitlist control, evidence comparing guided e-CBTi to pharmaceutical interventions is still insufficient and needs further exploration.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, since it involves comparing e-CBTi to trazodone, you might be required to continue using sleep-promoting medication if you are already doing so.
What data supports the effectiveness of the treatment e-CBTi for insomnia?
Research shows that digital cognitive behavioral therapy for insomnia (dCBT-I) is effective in treating insomnia, improving sleep quality, and enhancing overall well-being and quality of life. Studies also suggest that adding personalized telephone sessions to dCBT-I can provide additional benefits for those with chronic insomnia.12345
Is digital CBT-I safe for treating insomnia?
How does the treatment e-CBTi differ from other treatments for insomnia?
e-CBTi (digital cognitive behavioral therapy for insomnia) is unique because it is delivered online, making it more accessible and scalable compared to traditional face-to-face therapy. Unlike trazodone, a medication that alters brain activity during sleep, e-CBTi focuses on changing sleep-related behaviors and thoughts, which can also help with related issues like depression and anxiety.1281011
Research Team
Nazanin Alavi, MD FRCPC
Principal Investigator
Queen's University
Eligibility Criteria
This trial is for adults with non-organic insomnia who struggle to fall or stay asleep for at least 30 minutes. Participants must have internet access, use sleep meds thrice a week for 3 months, and understand English. It's not for pregnant individuals, those with untreated sleep disorders or substance abuse issues, current CBT patients, or people with significant untreated health problems.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomly assigned to either e-CBTi or trazodone treatment for 7 weeks
Follow-up
Participants are monitored for changes in sleep quality and insomnia severity after treatment
Open-label extension (optional)
Participants in the trazodone group may opt into the e-CBTi program after the 7-week study period
Treatment Details
Interventions
- e-CBTi
- Trazodone
e-CBTi is already approved in United States, European Union for the following indications:
- Insomnia
- Insomnia
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dr. Nazanin Alavi
Lead Sponsor
Dr. Nazanin Alavi
Lead Sponsor
Queen's University
Lead Sponsor
Online PsychoTherapy Clinic
Collaborator